CNS Drugs

, Volume 18, Supplement 2, pp 5–17

Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life

Review Article

Abstract

The increasing interest in the subjective wellbeing and quality of life (QoL) of patients with schizophrenia represents a conceptual extension of therapeutic outcome criteria. For a long time, the reduction of positive symptoms alone was the most important outcome parameter, but the development of atypical antipsychotic drugs in the early 1990s resulted in the adoption of more wide-reaching measures of therapeutic outcome. Patient satisfaction appears to be strongly related to their willingness to be or stay engaged in psychosocial and pharmacological treatment, and therefore to the symptomatic and functional outcome. Existing studies that deal with QoL and subjective wellbeing differ in their methodology and are difficult to compare because of varying underlying concepts of QoL or subjective wellbeing, different assessment scales or small sample sizes. Although QoL is a heterogeneous concept, it is clearly correlated with a number of factors, including illness, medication and stress process-related variables. Various protective factors have been identified; among these are personality traits, the degree of social support and treatment interventions. In clinical studies, atypical antipsychotic agents are associated with greater improvements in QoL and subjective wellbeing than are conventional agents. The reason for this is probably the ability of atypical agents to have a positive impact on factors most associated with QoL, such as negative and affective symptoms and drug tolerability. The most appropriate clinical approach to maximize QoL and subjective wellbeing for patients with schizophrenia is to use atypical antipsychotic drugs as a first-line treatment approach. Ideally, an atypical drug which is known not to have a negative effect on attention, affect or motivation should be chosen.

References

  1. 1.
    Albrecht GL, Fitzpatrick R, editors. A sociological perspective on health-related quality of life research. In: Advances in medical sociology — quality of life in health care. London: Jai Press; 1994Google Scholar
  2. 2.
    Lehman AF. The effects of psychiatric symptoms on quality of life assessments among the chronic mentally ill. Eval Prog Plann 1983; 6: 143–51CrossRefGoogle Scholar
  3. 3.
    Malm U, May PR, Dencker SJ. Evaluation of the quality of life of the schizophrenic outpatient: a checklist. Schizophr Bull 1981; 7: 477–87PubMedCrossRefGoogle Scholar
  4. 4.
    Bullinger M, Hasford J. Evaluating quality-of-life measures for clinical trials in Germany. Control Clin Trials 1991; 12(4 Suppl.): 91S–105SPubMedCrossRefGoogle Scholar
  5. 5.
    Awad AG. Quality of life of schizophrenic patients on medications and implications for new drug trials. Hosp Commun Psychiatry 1992; 43: 262–5Google Scholar
  6. 6.
    Zissi A, Barry MM, Cochrane R. A mediational model of quality of life for individuals with severe mental health problems. Psychol Med 1998; 28: 1221–30PubMedCrossRefGoogle Scholar
  7. 7.
    Ritsner M, Ben-Avi I, Ponizovsky A, et al. Quality of life and coping with schizophrenia symptoms. Qual Life Res 2003; 12: 1–9PubMedCrossRefGoogle Scholar
  8. 8.
    Ritsner M, Ponizovsky A, Endicott J, et al. The impact of side-effects of antipsychotic agents on life satisfaction of schizophrenia patients: a naturalistic study. Eur Neuropsychopharmacol 2002; 12: 31–8PubMedCrossRefGoogle Scholar
  9. 9.
    Ritsner M, Kurs R. Quality of life outcomes in mental illness: schizophrenia, mood and anxiety disorders. Expert Rev Pharmacoecon Outcomes Res 2003; 3: 89–99CrossRefGoogle Scholar
  10. 10.
    Angermeyer MC, Holzinger A, Kilian R, et al. Quality of life — as defined by schizophrenic patients and psychiatrists. Int J Soc Psychiatry 2001; 47: 34–42PubMedCrossRefGoogle Scholar
  11. 11.
    Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bull 1993; 19: 609–18PubMedCrossRefGoogle Scholar
  12. 12.
    Noll RL, Hoenkamp E, Nolen WA. Subjectieve bijwerkingen van neuroleptics. Nederlands Tijdschrift voor Geneeskunde 1991; 135: 2113–6PubMedGoogle Scholar
  13. 13.
    de Haan L. Patients perspectives, subjective experiences and attitudes of patients with recent onset schizophrenia. Amsterdam: University of Amsterdam; 2001.Google Scholar
  14. 14.
    Van Putten T, May RP. ‘Akinetic depression’ in schizophrenia. Arch Gen Psychiatry 1978; 35: 1101–7PubMedCrossRefGoogle Scholar
  15. 15.
    Wise RA. Neuroleptic-induced anhedonia. Recent studies. In: Tamminga CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology. New York: Raven Press; 1991. pp. 323–31Google Scholar
  16. 16.
    Emerich DF, Sanberg PR. Neuroleptic dysphoria. Biol Psychiatry 1991; 29: 201–3PubMedCrossRefGoogle Scholar
  17. 17.
    Lewander T. Neuroleptics an the neuroleptic-induced deficit syndrome. Acta Psychiatrica Scand 1994; 380 (Suppl.): 8–13CrossRefGoogle Scholar
  18. 18.
    Lambert M, Schimmelman B, Karow A, et al. Subjective well-being under neuroleptic treatment — concepts measurement, clinical relevance and implications for anti-psychotic treatment. Pharmacopsychiatry 2003; 36(Suppl. 3): 181–90Google Scholar
  19. 19.
    Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995; 10(Suppl. 3): 133–8PubMedGoogle Scholar
  20. 20.
    Awad AG. Antipsychotic medications in schizophrenia: how satisfied are our patients? Management issues in schizophrenia: patient satisfaction, compliance and outcomes in schizophrenia. Clear Perspect 1999; 2: 1–6Google Scholar
  21. 21.
    Cabeza IG, Amador MS, Lopez CA, et al. Subjective response to antipsychotics in schizophrenic patients: clinical implications and related factors. Schizophr Res 2000; 41: 349–55PubMedCrossRefGoogle Scholar
  22. 22.
    Browne S, Garavan J, Gervin M, et al. Quality of life in schizophrenia: insight and subjective response to neuroleptics. J Nerv Ment Dis 1998; 186: 74–8PubMedCrossRefGoogle Scholar
  23. 23.
    Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998; 28: 165–72PubMedCrossRefGoogle Scholar
  24. 24.
    Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 1992; 30: 473–83PubMedCrossRefGoogle Scholar
  25. 25.
    Diamond R, Becker M. The Wisconsin Quality of Life Index: a multidimensional model for measuring quality of life. J Clin Psychiatry 1999; 60(Suppl. 3): 29–31PubMedGoogle Scholar
  26. 26.
    Bergner M, Bobbitt RA, Carter WB, et al. The Sickness Impact Profile: development and final revision of a health status measure. Med Care 1981; 19: 787–805PubMedCrossRefGoogle Scholar
  27. 27.
    Oliver JP, Huxley PJ, Priebe S, et al. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Soc Psychiatry Psychiatr Epidemiol 1997; 32: 76–83PubMedCrossRefGoogle Scholar
  28. 28.
    Pukrop R, Moller HJ, Sass H, et al. Quality of life. Construct validation and the development of a modular system. Nervenartz 1999; 70: 41–53CrossRefGoogle Scholar
  29. 29.
    Lehman AF. A quality of life interview for the chronically mentally ill. Eval Program Plann 1988; 11: 51–62CrossRefGoogle Scholar
  30. 30.
    Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388–98PubMedCrossRefGoogle Scholar
  31. 31.
    Jaeger J, Bitter I, Czobor P, et al. The measurement of subjective experience in schizophrenia: the subjective deficit syndrome scale. Comprehen Psychiatry 1990; 31: 216–26CrossRefGoogle Scholar
  32. 32.
    Singh MM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst 1976; 37: 191–6PubMedGoogle Scholar
  33. 33.
    Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983; 13: 177–83PubMedCrossRefGoogle Scholar
  34. 34.
    Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001; 50: 79–88PubMedCrossRefGoogle Scholar
  35. 35.
    Voruganti LN, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scale to measure subjective aspects of antipsychotic drug therapy in schizophrenia. Schizophr Res 2002; 56: 37–46PubMedCrossRefGoogle Scholar
  36. 36.
    Carpiniello B, Lai GL, Pariante CM, et al. Symptoms, standards of living and subjective quality of life: a comparative study of schizophrenic and depressed outpatients. Acta Psychiatrica Scand 1997; 96: 235–41CrossRefGoogle Scholar
  37. 37.
    Skantze K, Malm U, Dencker SJ, et al. Comparison of quality of life with standard of living in schizophrenic out-patients. Br J Psychiatry 1992; 161: 797–801PubMedCrossRefGoogle Scholar
  38. 38.
    Lehman AF, Postrado LT, Rachuba LT. Convergent validation of quality of life assessments for persons with severe mental illnesses. Qual Life Res 1993; 2: 327–33PubMedCrossRefGoogle Scholar
  39. 39.
    Hansson L, Middelboe T, Merinder L, et al. Predictors of subjective quality of life in schizophrenic patients living in the community. A Nordic multicentre study. Int J Soc Psychiatry 1999; 45: 247–58PubMedCrossRefGoogle Scholar
  40. 40.
    Browne S, Clarke M, Gervin M, et al. Determinants of quality of life at first presentation with schizophrenia. Br J Psychiatry 2000; 176: 173–6PubMedCrossRefGoogle Scholar
  41. 41.
    Ritsner M, Kurs R, Gibel A, et al. Predictors of quality of life in major psychoses: a naturalistic follow-up study. J Clin Psychiatry 2003; 64: 308–15PubMedCrossRefGoogle Scholar
  42. 42.
    Awad AG, Hogan TP, Voruganti LN, et al. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995; 10(Suppl. 3): 123–32PubMedGoogle Scholar
  43. 43.
    de Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology (Berl) 2002; 162: 24–8CrossRefGoogle Scholar
  44. 44.
    Ritsner M. Predicting changes in domain-specific quality of life of schizophrenia patients. J Nerv Ment Dis 2003; 191: 287–94PubMedGoogle Scholar
  45. 45.
    Tollefson GD, Andersen SW, Tran PV The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone. Biol Psychiatry 1999; 46: 365–73PubMedCrossRefGoogle Scholar
  46. 46.
    Huppert JD, Smith TE. Longitudinal analysis of subjective quality of life in schizophrenia: anxiety as the best symptom predictor. J Nerv Ment Dis 2001; 189: 669–75PubMedCrossRefGoogle Scholar
  47. 47.
    Bow-Thomas CC, Velligan DI, Miller AL, et al. Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization. Psychiatry Res 1999; 86: 131–42PubMedCrossRefGoogle Scholar
  48. 48.
    Browne S, Roe M, Lane A, et al. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr Scand 1996; 94: 118–24PubMedCrossRefGoogle Scholar
  49. 49.
    Giner J, Ibanez E, Cervera S, et al. Subjective experience and quality of life in schizophrenia [in Spanish]. Actas Esp Psiquiatr 2001; 29: 233–42PubMedGoogle Scholar
  50. 50.
    Ho BC, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998; 155: 1196–201PubMedGoogle Scholar
  51. 51.
    Moritz S, Krausz M, Gottwalz E, et al. Cognitive dysfunction at baseline predicts symptomatic 1-year outcome in first-episode schizophrenics. Psychopathology 2000; 33: 48–51PubMedCrossRefGoogle Scholar
  52. 52.
    Heslegrave RJ, Awad AG, Voruganti LN. The influence of neurocognitive deficits and symptoms on quality of life in schizophrenia. J Psychiatry Neurosci 1997; 22: 235–43PubMedGoogle Scholar
  53. 53.
    Kaiser W. Cognitive effects of antipsychotics in schizophrenia and relationship to quality of life. Br J Psychiatry 2000; 176: 92–3PubMedCrossRefGoogle Scholar
  54. 54.
    Aksaray G, Oflu S, Kaptanoglu C, et al. Neurocognitive deficits and quality of life in outpatients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2002; 26: 1217–9PubMedCrossRefGoogle Scholar
  55. 55.
    Brekke JS, Kohrt B, Green MF. Neuropsychological functioning as a moderator of the relationship between psychosocial functioning and the subjective experience of self and life in schizophrenia. Schizophr Bull 2001; 27: 697–708PubMedCrossRefGoogle Scholar
  56. 56.
    Norman RM, Malla AK, McLean T, et al. The relationship of symptoms and level of functioning in schizophrenia to general wellbeing and the Quality of Life Scale. Acta Psychiatr Scand 2000; 102: 303–9PubMedCrossRefGoogle Scholar
  57. 57.
    Ritsner M, Modai I, Endicott J, et al. Differences in quality of life domains and psychopathologic and psychosocial factors in psychiatric patients. J Clin Psychiatry 2000; 61:880–9; quiz 90PubMedCrossRefGoogle Scholar
  58. 58.
    Doyle M, Flanagan S, Browne S, et al. Subjective and external assessments of quality of life in schizophrenia: relationship to insight. Acta Psychiatr Scand 1999; 99: 466–72PubMedCrossRefGoogle Scholar
  59. 59.
    Lysaker PH, Bell MD, Bryson GJ, et al. Insight and interpersonal function in schizophrenia. J Nerv Ment Dis 1998; 186: 432–6PubMedCrossRefGoogle Scholar
  60. 60.
    Day JC, Kinderman P, Bentall R. A comparison of patients’ and prescribers’ beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiatr Scand 1998; 97: 93–7PubMedCrossRefGoogle Scholar
  61. 61.
    Gervin M, Browne S, Garavan J, et al. Dysphoric subjective response to neuroleptics in schizophrenia: relationship to extrapyramidal side effects and symptomatology. Eur Psychiatry 1999; 14: 405–9PubMedCrossRefGoogle Scholar
  62. 62.
    Lambert M, Conus P, Eide P, et al. Impact of present and past side effects on the attitude towards typical anti-psychotic treatment. European Psychiatry submitted.Google Scholar
  63. 63.
    Van Putten T, Marder SR. Behavioral toxicity of anti-psychotic drugs. J Clin Psychiatry 1987; 48 (Suppl.): 13–9Google Scholar
  64. 64.
    Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia. Psychiatr Serv 2003; 54: 565–7PubMedCrossRefGoogle Scholar
  65. 65.
    Hofer A, Kemmler G, Eder U, et al. Attitudes toward antipsychotics among outpatient clinic attendees with schizophrenia. J Clin Psychiatry 2002; 63: 49–53PubMedCrossRefGoogle Scholar
  66. 66.
    Knudstorp TB, Gerlach J. Quality of life (QoL) in chronic schizophrenic patients related to symptoms, side-effects and subjective distress. In: Proceedings of the XIth World Congress on Psychiatry. Hamburg, Germany, 1999Google Scholar
  67. 67.
    Jarema M, Murawiec S, Szafranski T, et al. Subjective and objective evaluation of treating schizophrenia with classic or atypical drugs [in Polish]. Psychiatr Pol 2001; 35: 5–19PubMedGoogle Scholar
  68. 68.
    Van Putten T, May PR, Marder SR. Response to anti-psychotic medication: the doctor’s and the consumer’s view. Am J Psychiatry 1984; 141: 16–9PubMedGoogle Scholar
  69. 69.
    Ritsner M, Modai I, Ponizovsky A. Assessing psychological distress in psychiatric patients: validation of the Talbieh Brief Distress Inventory. Compr Psychiatry 2002; 43: 229–34PubMedCrossRefGoogle Scholar
  70. 70.
    Fakhoury WK, Wright D, Wallace M. Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline. Int Clin Psychopharmacol 2001; 16: 153–62PubMedCrossRefGoogle Scholar
  71. 71.
    Lasalvia A, Ruggeri M, Santolini N. Subjective quality of life: its relationship with clinician-rated and patient-rated psychopathology. The South-Verona Outcome Project 6. Psychother Psychosom 2002; 71: 275–84PubMedCrossRefGoogle Scholar
  72. 72.
    Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br J Psychiatry Suppl 1993; 22: 39–44Google Scholar
  73. 73.
    Eklund M, Backstrom M, Hansson L. Personality and self-variables: important determinants of subjective quality of life in schizophrenia out-patients. Acta Psychiatr Scand 2003; 108: 134–43PubMedCrossRefGoogle Scholar
  74. 74.
    Bechdolf A, Klosterkotter J, Hambrecht M, et al. Determinants of subjective quality of life in post acute patients with schizophrenia. Eur Arch Psychiatry Clin Neurosci 2003; 253: 228–35PubMedCrossRefGoogle Scholar
  75. 75.
    Bengtsson-Tops A, Hansson L. Quantitative and qualitative aspects of the social network in schizophrenic patients living in the community. Relationship to sociodemographic characteristics and clinical factors and subjective quality of life. Int J Soc Psychiatry 2001; 47: 67–77PubMedCrossRefGoogle Scholar
  76. 76.
    Borge L, Martinsen EW, Ruud T, et al. Quality of life, loneliness, and social contact among long-term psychiatric patients. Psychiatr Serv 1999; 50: 81–4PubMedGoogle Scholar
  77. 77.
    Hansson L, Eklund M, Bengtsson-Tops A. The relationship of personality dimensions as measured by the temperament and character inventory and quality of life in individuals with schizophrenia or schizoaffective disorder living in the community. Qual Life Res 2001; 10: 133–9PubMedCrossRefGoogle Scholar
  78. 78.
    Karow A, Naber D. Subjective well-being and quality of life under atypical antipsychotic treatment. Psychopharmacology (Berl) 2002; 162: 3–10CrossRefGoogle Scholar
  79. 79.
    Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000; 43: 135–45PubMedCrossRefGoogle Scholar
  80. 80.
    Voruganti L, Cortese L, Owyeumi L, et al. Switching from conventional to novel antipsychotic drugs: results of a prospective naturalistic study. Schizophr Res 2002; 57: 201–8PubMedCrossRefGoogle Scholar
  81. 81.
    Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693–702PubMedCrossRefGoogle Scholar
  82. 82.
    de Haan L, Peters B, Dingemans P, et al. Attitudes of patients toward the first psychotic episode and the start of treatment. Schizophr Bull 2002; 28: 431–42PubMedCrossRefGoogle Scholar
  83. 83.
    Voruganti LN, Heslegrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Nerv Ment Dis 1997; 185: 463–5PubMedCrossRefGoogle Scholar
  84. 84.
    Dollfus S, Ribeyre JM, Petit M. Objective and subjective extrapyramidal side effects in schizophrenia: their relationships with negative and depressive symptoms. Psychopathology 2000; 33: 125–30PubMedCrossRefGoogle Scholar
  85. 85.
    Casey DE. Motor and mental aspects of extrapyramidal syndromes. Int Clin Psychopharmacol 1995; 10(Suppl. 3):105–14PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department for Psychiatry and Psychotherapy, University of HamburgCentre for Psychosocial MedicineHamburgGermany

Personalised recommendations